Send to

Choose Destination
Oncology. 1996 Jun;53 Suppl 1:102-9.

Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs.

Author information

Division of Biology, Glaxo Research and Development Ltd., Ware, Herts., UK.


The introduction of 5-HT3 antagonists, such as ondansetron, as antiemetic agents has transformed the management of patients receiving chemotherapy or radiation therapy. Studies in animal models with NK1 antagonists suggest that these represent a new class of antiemetic agents having a broader spectrum of activity than 5-HT3 antagonists. Compounds of this class may prove to be more effective in man against delayed emesis induced by cisplatin, post-operative nausea and vomiting and motion sickness. Thus, they have the potential to complement 5-HT3 antagonists and so provide a further advance in the management of nausea and vomiting.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center